Article Versions Notes

Immovilli P, Morelli N, Terracciano C, Rota E, Marchesi E, Vollaro S, De Mitri P, Zaino D, Bazzurri V, Guidetti D. Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. Neurology International. 2022; 14(2):368-377. https://doi.org/10.3390/neurolint14020030

Immovilli, Paolo, Nicola Morelli, Chiara Terracciano, Eugenia Rota, Elena Marchesi, Stefano Vollaro, Paola De Mitri, Domenica Zaino, Veronica Bazzurri, and Donata Guidetti. 2022. "Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach" Neurology International 14, no. 2: 368-377. https://doi.org/10.3390/neurolint14020030

Immovilli, P., Morelli, N., Terracciano, C., Rota, E., Marchesi, E., Vollaro, S., De Mitri, P., Zaino, D., Bazzurri, V., & Guidetti, D. (2022). Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. Neurology International, 14(2), 368-377. https://doi.org/10.3390/neurolint14020030